Su­per-se­cre­tive an­ti-ag­ing biotech Cal­i­co tees up the first vis­i­ble clin­i­cal tri­al of an ex­per­i­men­tal drug. And it’s for can­cer?

Over the past 7 years, Cal­i­co has been so much more than your av­er­age, run-of-the-mill se­cre­tive biotech play­ers. It’s a rid­dle, wrapped in a mys­tery, in­side an enig­ma, to re­pur­pose an old Win­ston Churchill line dat­ing from the time he con­front­ed the Iron Cur­tain sur­round­ing Stal­in’s thoughts.

Launched by in­dus­try leg­end Art Levin­son of Genen­tech fame, with the in­fi­nite­ly deep pock­ets of Google for sup­port, one of the few big head­lines the an­ti-ag­ing biotech has sparked fo­cused on a ma­jor al­liance with Ab­b­Vie — a gi­ant out­fit that con­verse­ly likes to show off its drug prospects when­ev­er it can. To­geth­er, they’ve been fo­cused on dis­eases that lim­it life span — quite an arc of ail­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.